For primary adenocarcinomas of the colon or rectum, tumour stage is still the best predictor of survival after resection. However, among patients diagnosed with UICC stage II (pT3--pT4, N0, M0) colorectal cancer (CRC), up to 35% will experience recurrence ([@bib18]; [@bib9]). Several molecular and gene-expression profiling biomarkers have been proposed as markers of poor prognosis in stage II patients, but none has yet been validated in a large-scale prospective clinical trial ([@bib3]; [@bib6]; [@bib1]). We report on the stage-dependent prognostic significance of chromosomal instability (CIN) and microsatellite instability (MSI) in a large consecutive series of colorectal carcinomas treated in one hospital with a defined catchment area.

DNA aneuploidy, an accepted marker for CIN, is found in the majority of sporadic CRC and has been linked to poor prognosis ([@bib11]; [@bib13]). Two recent meta-analyses of 67 separate studies demonstrated poorer overall survival (OS) for patients with stage II--III colorectal tumours showing CIN (HR 1.45 (1.33--1.55)) ([@bib2]; [@bib20]).

Microsatellite instability is a marker for relatively good prognosis in CRC, also supported by meta-analysis ([@bib7]). In this study we have had access to data from a recent PCR study of the occurrence of MSI in the present material ([@bib12]).

Traditionally, CIN and MSI have been seen as different and complementary pathways to CRC. However, studies including other biomarkers have shown that the picture is more complicated ([@bib19]; [@bib8]; [@bib4]). This is the first study to examine the stage-related prognostic impacts of CIN and MSI together in one large consecutive patient series.

Material and methods
====================

Patient data
------------

This study is based on consecutive primary CRCs referred to Aker University Hospital in Oslo, Norway, from 1993 to 2003. The series comprised 1274 patients out of which 952 underwent major resection. Median age at presentation was 74 (19--96) years. Details of preoperative investigations, operative procedures, histopathological examinations, patient follow-up and mortality data have been reported previously ([@bib14]; [@bib17]).

Exclusions
----------

We excluded 44 patients who died of post-operative complications and 53 cases where the nuclear monolayer or DNA content histograms were unsatisfactory, resulting in a data set containing crude OS, clinical data and DNA content histograms for 855 colorectal adenocarcinomas at stages I--IV.

Recurrence analysis
-------------------

For time to recurrence (TTR) analysis, a further restricted data set (*n*=579) was prepared by eliminating patients presenting with metastatic disease, residual cancer (R\>0), unknown cause of death or synchronous lesions ([@bib15]). Median patient age at surgery was 73 years (30--94).

Tumour location
---------------

Tumours located proximal to the splenic flexure were considered as proximal (right), while tumours located at or distal to the splenic flexure were considered to be distal (left). [Supplementary Table S1](#sup1){ref-type="supplementary-material"} shows the anatomical distribution of tumours in the TTR data set.

Tissue processing and DNA ploidy measurement
--------------------------------------------

Automated image-based DNA cytometry was performed as previously described ([@bib10]). Nuclear DNA content histograms were classified as DNA diploid, DNA tetraploid or DNA aneuploid. Non-diploid histograms were taken as indicative of the presence of CIN.

Microsatellite instability assessment
-------------------------------------

Details of PCR MSI determination in this material were recently described ([@bib12]).

Statistical analysis
--------------------

Overall survival was computed in months from the date of surgery until death or May 2010. Death from any cause was registered as an event (data from the Norwegian Death Registry). Living patients were censored at the end of the study (mean follow-up: 69 months). In analyses of TTR, local or distant recurrence or death from CRC were registered as events, and patients were censored at death from other causes or at study closure.

Significance of associations between categorical variables was evaluated using Fisher\'s exact test. The Mantel--Cox log-rank test was used for univariate analysis. For multivariate evaluation of prognostic impact we used a Cox proportional hazards regression model. In multivariate models including CIN status we excluded MSI due to the high correlation between the two variables. Separate analysis of the prognostic impact of CIN in the first and second 5-year periods supported validity of the proportional hazard assumption. All statistics were generated using SPSS 20.0 (IBM Corporation, Armonk, NY, USA). Statistical significance was defined as two-sided *P*\<0.05.

The study was performed according to the Helsinki Declaration and approved by the Norwegian Regional Committees for Medical Research (REK; \#1.2005.1629).

Results
=======

Overall survival
----------------

Of 855 patients, 291 were alive at the end of follow-up (mean 69 months). [Figure 1](#fig1){ref-type="fig"} shows Kaplan--Meier OS curves for all stages.

Chromosomal instability and MSI status were strongly negatively associated (*P*\<0.001) such that individual tumours were likely to show either MSI or CIN.

[Supplementary Table S2](#sup1){ref-type="supplementary-material"} shows the results of univariate and multivariate analyses on prognostic factors and OS. Chromosomal instability was a significant prognostic marker in patients with stage II disease in a Cox regression model that included age, grade, R-status and type of surgery (*n*=348; HR 1.46 (1.06--1.99), *P*=0.019). Probably because of the high percentage of stage II patients overall, CIN also emerged as a significant predictor of survival in multivariate Cox regression analysis for the entire patient cohort (*n*=855; HR 1.24 (1.02--1.52, *P*=0.031).

Microsatellite instability was borderline significant as predictor of univariate improved OS in stage II (*P*=0.055), but not in stage III. Microsatellite instability was a significant predictor of improved OS in the entire stage I--IV cohort (*P*=0.007) ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}). In line with previous reports, MSI tumours were predominantly DNA diploid and located proximally, whereas the microsatellite stable (MSS) tumours were predominantly DNA non-diploid and distal.

Recurrence
----------

Of the 579 patients in the TTR data set, 220 (38%) experienced recurrence (153) or died of CRC (67) after a median of 23 months (range 1--120). In stage II disease the 10-year estimated recurrence rate was 42% (Table 2). Clinicopathological features of the TTR data set are summarised in [Table 1](#tbl1){ref-type="table"}.

CIN and recurrence
------------------

Analysis for prognostic factors in stage II cases alone and in the entire TTR data set are shown in [Table 2](#tbl2){ref-type="table"}. As in the OS analysis, CIN status was found to be significant in univariate (*P*=0.001) and multivariate analysis in stage II that included age, three levels of histology grade and emergency *vs* elective surgery, (HR 2.19 (1.35--3.55), *P*=0.002). In the stage II TTR cohort, the independent prognostic factors for recurrence were CIN and urgency of surgery. Among the stage II patients with CIN (*n*=182) 43% experienced recurrence, compared with 22% among DNA diploid stage II patients (*n*=96).

In stage I tumours, we observed a similar trend as for stage II, but this difference failed to reach statistical significance, due to small patient numbers. Among stage III CRCs, no prognostic impact of CIN was found ([Figure 2](#fig2){ref-type="fig"}). This pattern was similar for both colon and rectal stage III cancers ([Figure 3](#fig3){ref-type="fig"}).

Taking stages I--III together, CIN continued to be a significant prognostic factor in univariate analysis (*P*=0.006) and it retained significance as an independent prognostic factor in Cox multivariate analysis (HR 1.56 (1.13--2.15), *P*=0.007).

In order to investigate the effect of heterogeneity for CIN between the three stage groups we included the interaction term CIN\*stage in the Cox regression model and found that both the interaction term and stage were significant in the model, while CIN was not. We may interpret this as stage having an effect regardless of CIN status, while the effect of CIN is different in the three stage groups. The prognostic effect of CIN in the three stage groups is illustrated in [Figure 4](#fig4){ref-type="fig"}.

MSI and recurrence
------------------

The positive prognostic impact of MSI among stage II, but not stage III, colorectal tumours from the present material has already been reported ([@bib12]). In our TTR data set, MSI was borderline significant (*P*=0.049) in univariate analysis, but not significant (*P*=0.094) in multivariate analysis in stage II ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}).

[Figure 2](#fig2){ref-type="fig"} shows Kaplan--Meier plots for relapse of the different combinations of MSI and CIN status as stratified by stage. Tables in the same figure show how the relationship between MSI/MSS and DNA ploidy status was dependent on stage. There were no relapses among the 10 patients with stage I MSI tumours. Fifty-three patients presented with stage II MSI tumours, of which 37 were diploid, 3 were aneuploid and 13 were tetraploid. The relatively good prognosis of the 104 MSI and diploid MSS stage II lesions contrasted with the poor prognosis of 154 patients with the CIN-MSS phenotype. Patients with stage III tumours had a uniformly high level of relapse that was independent of both MSI and CIN.

[Figure 3](#fig3){ref-type="fig"} compares the stage-dependent prognostic impact of MSI with that of CIN in the colon and rectum. Among stage II lesions in both locations non-diploid MSS tumours show a significantly increased probability of relapse. As reported elsewhere, MSI tumours were rare in the rectum (5 of 173 tumours). In the colon, diploid MSS tumours had similar relapse rates to MSI tumours.

In total, 133 (25%) of the patients did not follow the diploid/MSI--non-diploid/MSS pattern.

Discussion
==========

This study is the first to report survival data in relation to CIN/MSI after stratifying according to tumour stage. In fact few survival studies have measured CIN and MSI in the same resection specimens. [Supplementary Table S4](#sup1){ref-type="supplementary-material"} summarises some relevant findings from eight studies as well as from the present report. Despite the often quoted 'typical incidence\' figures of 85% CIN and 15% MSI in CRC, the incidence of CIN varied between 35--70% in these studies, while MSI varied from 5--23% and tumours showing neither CIN nor MSI were common (19--52%). In the light of the present finding of a marked stage-specific difference in the prognostic impact of both CIN and MSI, the variability between results in [Supplementary Table S4](#sup1){ref-type="supplementary-material"} can be seen as following inclusion of different proportions of stage I--IV material in the different studies.

Twenty-five per cent of the stage II cancers with MSI in this study were DNA tetraploid, and these carried good prognosis equal to that of the other MSI tumours ([Figure 2](#fig2){ref-type="fig"}). The biological basis of this difference from MSS tetraploidy remains to be clarified.

There are advantages and disadvantages with all end points. For OS, non-cancer-related deaths add variability. This is to some degree taken into account by censoring at 5 years after surgery. With TTR, inclusion of cancer-related deaths is controversial as this is often hard to demonstrate. However, the main conclusions regarding CIN and MSI remain the same regardless of end point, although *P*-values and hazard ratios change to some degree. [Supplementary Figure S1](#sup1){ref-type="supplementary-material"} illustrates this for CIN in the data sets representing both OS and TTR end points. For direct comparison with the previously published work on MSI status in this material we include figures in [Supplementary Figure S1](#sup1){ref-type="supplementary-material"} for the prognostic impact of CIN using the 5-year relapse free survival (RFS) model employed by [@bib12]. Interestingly, the 5-year RFS *P*-values for CIN status are higher than the corresponding *P*-values for OS and TTR. A possible explanation is that CIN has a continuing prognostic impact after 5 years, which is not taken into account with the 5-year end point.

We report that stage II tumours with MSI have very similar prognosis to diploid MSS lesions. CIN occurred more often than MSI, and both CIN and MSI were confirmed in our TTR analysis as independent predictors of recurrence in stage II CRC. Although rarely occurring outside of the proximal colon, MSI is currently seen as a clinically useful predictor of good outcome for patients with stage II CRC. This is supported by positive results from retrospective trials such as the present study in which multivariate analysis shows MSI to have significant predictive value. But from the point of view of an individual patient, the clinical picture is less than ideal -- we found MSI in only 51 of the stage II resections in this study, and 13 of these patients went on to experience recurrence. As for CIN, our results support the present consensus that CIN is also an independent prognostic marker in stage II CRC, and possibly a more useful marker than MSI ([@bib16]; [@bib13]). But again, from the individual patient\'s point of view CIN is less than ideal. Of the 182 stage II resections with CIN in the TTR cohort, 75 were associated with relapse, while there were 23 recurrences among the 96 patients with diploid resections. Adding CIN to the MSI results produced only a small improvement in prediction for relapse. Can the clinical usefulness of DNA cytometry be improved? This remains a very promising area for research. Here we have used the most robust binary DNA histogram classification (CIN or DNA diploid), but it is clear that a great deal more information still remains to be extracted from the Feulgen images of tumour nuclei ([@bib5]).
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![**Kaplan--Meier overall survival for patients with colorectal cancer stage I-IV.**](bjc2014133f1){#fig1}

![**Kaplan--Meier plots of time to recurrence among patients presenting with stage I (A), stage II (C) and stage III (E) tumours.** Each panel shows relapses for four separate categories of tumour phenotype: diploid MSI (green line), non-diploid MSI (purple line), diploid MSS (blue line) and non-diploid MSS (orange line). To the right of each panel is a table (**B**, **D** and **F**) showing the distribution of DNA ploidy status categories among MSI and MSS tumours in that tumour stage. A forest plot (**G**) summarises the effect of MSI/CIN in the different stages.](bjc2014133f2){#fig2}

![**Forest plot of effect of CIN for colon and rectal tumour stages I--III.**](bjc2014133f3){#fig3}

![**Forest plot of effect of CIN in stages I--III colorectal tumours.**](bjc2014133f4){#fig4}

###### Clinicopathological data for the time to recurrence data set

                               **All tumours**   **DNA diploid**   **DNA non-diploid**                
  ---------------------------- ----------------- ----------------- --------------------- ------ ----- ------
  Relapse                      220               38.0              55                    30.1   165   41.7
  No relapse                   359               62.0              128                   69.9   231   58.3
  **MSI status**                                                                                      
  MSS                          452               83.9              108                   63.5   344   93.2
  MSI                          87                16.1              62                    36.5   25    6.8
  **Age at surgery (years)**                                                                          
  ⩽72                          289               49.9              92                    50.3   197   49.7
  \>72                         290               50.1              91                    49.7   199   50.3
  **Gender**                                                                                          
  Male                         289               49.9              75                    41.0   214   54.0
  Female                       290               50.1              108                   59.0   182   46.0
  **Stage**                                                                                           
  I                            112               19.3              37                    20.2   75    18.9
  II                           278               48.0              96                    52.5   182   46.0
  III                          189               32.6              50                    27.3   139   35.1
  **pT status**                                                                                       
  pT1                          27                4.7               10                    5.5    17    4.3
  pT2                          103               17.8              32                    17.5   71    17.9
  pT3                          415               71.7              135                   73.8   280   70.7
  pT4                          34                5.9               6                     3.3    28    7.1
  **pN status**                                                                                       
  N0                           389               67.3              133                   72.7   256   64.8
  N1                           152               26.3              41                    22.4   111   28.1
  N2                           37                6.4               9                     4.9    28    7.1
  **Grade**                                                                                           
  H (well diff.)               58                10.0              19                    10.4   39    9.8
  M (moderately diff.)         453               78.2              127                   69.4   326   82.3
  L (poorly diff.)             63                10.9              34                    18.6   29    7.3
  Mucinous diff.               5                 0.9               3                     1.6    2     0.5
  **Location**                                                                                        
  Proximal colon               227               39.2              90                    49.2   137   34.6
  Distal colon                 179               30.9              48                    26.2   131   33.1
  Rectum                       173               29.9              45                    24.6   128   32.3
  **Type of surgery**                                                                                 
  Elective                     519               89.6              171                   93.4   348   87.9
  Acute                        60                10.4              12                    6.6    48    12.1

Abbreviations: diff.=differentiated; H=high; L=low; M=moderate.

###### Time to recurrence related to prognostic factors for stage I--III and stage II colorectal cancer patients

                            **Univariate analysis all**   **Univariate analysis stage II**   **Cox multivariate analysis all**  **Cox multivariate analysis stage II**                                                                                 
  ------------------------ ----------------------------- ---------------------------------- ----------------------------------- ---------------------------------------- ----- ------ ------ ------- ------ ------------ --------- ------ ------------ -------
  Age at surgery (years)                                                                                                        0.003                                                        0.060                       0.003                             
   ⩽72                                  289                             0.73                               0.64                                                           130   0.75   0.65           Ref                                                  
   \>72                                 290                             0.62                               0.49                                                           148   0.67   0.50           1.51   1.15--1.98                                    
  DNA ploidy                                                                                                                    0.006                                                        0.001                       0.007                          0.002
   Diploid                              183                             0.74                               0.66                                                           96    0.83   0.74           Ref                           Ref                    
   Non-diploid                          396                             0.64                               0.53                                                           182   0.65   0.49           1.56   1.13--2.15             2.19   1.35--3.55      
  MSI status                                                                                                                    0.097                                                        0.049                                                         
   MSS                                  452                             0.65                               0.54                                                           205   0.67   0.53                                                                
   MSI                                  87                              0.72                               0.64                                                           53    0.80   0.69                                                                
  Stage                                                                                                                         \<0.001                                                                                  \<0.001                           
   I                                    112                             0.85                               0.81                                                                                       Ref                                                  
   II                                   278                             0.71                               0.58                                                                                       2.01   1.22--3.32                                    
   III                                  189                             0.52                               0.41                                                                                       3.88   2.36--6.39                                    
  Grade                                                                                                                         0.002                                                        0.986                       0.001                             
   H (well diff.)                       58                              0.78                               0.74                                                           16    0.69   0.69           Ref                                                  
   M (moderately diff.)                 453                             0.69                               0.58                                                           227   0.71   0.58           1.45   0.84--2.52                                    
   L (poorly diff.)                     63                              0.52                               0.40                                                           31    0.73   0.56           2.76   1.46--5.22                                    
  pT stage                                                                                                                      \<0.001                                                      0.275                                                         
   pT1                                  27                              0.88                               0.88                                                                                                                                            
   pT2                                  103                             0.82                               0.77                                                                                                                                            
   pT3                                  415                             0.64                               0.52                                                           261   0.71   0.59                                                                
   pT4                                  34                              0.51                               0.34                                                           17    0.65   0.49                                                                
  Gender                                                                                                                        0.953                                                        0.770                                                         
   Male                                 289                             0.67                               0.57                                                           138   0.72   0.58                                                                
   Female                               290                             0.68                               0.57                                                           140   0.70   0.58                                                                
  Location                                                                                                                      0.723                                                        0.483                                                         
   Proximal colon                       227                             0.68                               0.54                                                           129   0.77   0.58                                                                
   Distal colon                         179                             0.65                               0.56                                                           82    0.67   0.58                                                                
   Rectum                               173                             0.70                               0.62                                                           67    0.66   0.60                                                                
  Type of surgery                                                                                                               \<0.001                                                      0.001                       0.001                          0.006
   Elective                             519                             0.70                               0.59                                                           244   0.73   0.61           Ref                           Ref                    
   Acute                                60                              0.48                               0.36                                                           34    0.53   0.38           1.84   1.27--2.69             2.04   1.23--3.38      

Abbreviations: CI=confidence interval; diff.= differentiated; H=high; HR=hazard ratio; L=low; M=moderate; No=number; pts=patients; Ref=reference; TTR=time to recurrence; y=year.
